To explore the inhibition effect of RPS6KA2 on ovarian cancer, we tested the mRNA and protein expression of RPS6KA2 in five ovarian cancer cell lines (HO8910, SKOV3, OVCAR3, A2780 and COC2) and a normal ovarian cell line (IOSE386), identical with the tumor tissue profiles, ovarian cancer cells expressed lower levels of RPS6KA2 than that in normal cell (Figure 2A). Here, RPS6KA2 is linked to neoplasm.